VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

This study has been completed.
Information provided by:
Vanda Pharmaceuticals Identifier:
First received: February 3, 2006
Last updated: February 3, 2014
Last verified: February 2014

The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.

Condition Intervention Phase
Drug: VEC-162
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia

Further study details as provided by Vanda Pharmaceuticals:

Primary Outcome Measures:
  • Time to fall asleep

Secondary Outcome Measures:
  • Amount of time spent asleep and awake during the night, sleep quality, safety and tolerability

Estimated Enrollment: 400
Study Start Date: February 2006
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   21 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects with no medical, psychiatric or current sleep disorders.
  • Subject must sign a written consent form.

Exclusion Criteria:

  • Recent history of night shift work or jet lag.
  • Prior experience sleeping in a sleep lab environment.
  • History of sleep disorders.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00291187

United States, Alabama
Vanda Investigational Site
Birmingham, Alabama, United States
United States, Arizona
Vanda Investigational Site
Phoenix, Arizona, United States
United States, California
Vanda Investigational Site
San Diego, California, United States
Vanda Investigational Site
San Francisco, California, United States
Vanda Investigational Site
Santa Monica, California, United States
United States, Florida
Vanda Investigational Site
Miami, Florida, United States
Vanda Investigational Site
Naples, Florida, United States
Vanda Investigational Site
Pembroke Pines, Florida, United States
Vanda Investigational Site
St. Petersburg, Florida, United States
United States, Georgia
Vanda Investigational Site
Atlanta, Georgia, United States
United States, Kansas
Vanda Investigational Site
Overland Park, Kansas, United States
United States, Maryland
Vanda Investigational Site
Chevy Chase, Maryland, United States
United States, New York
Vanda Investigational Site
New York, New York, United States
Vanda Investigational Site
Rochester, New York, United States
United States, North Carolina
Vanda Investigational Site
Raleigh, North Carolina, United States
United States, Ohio
Vanda Investigational Site
Cincinnati, Ohio, United States
United States, South Carolina
Vanda Investigational Site
Columbia, South Carolina, United States
United States, Texas
Vanda Investigational Site
Austin, Texas, United States
Vanda Investigational Site
Plano, Texas, United States
Sponsors and Collaborators
Vanda Pharmaceuticals
  More Information

No publications provided by Vanda Pharmaceuticals

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00291187     History of Changes
Other Study ID Numbers: VP-VEC-162-3101
Study First Received: February 3, 2006
Last Updated: February 3, 2014
Health Authority: United States: Food and Drug Administration processed this record on September 16, 2014